Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bio-Path Holdings, Inc. - Common Stock (NQ: BPTH )

0.8240 +0.0040 (+0.49%)
Streaming Delayed Price Updated: 11:58 AM EST, Jan 21, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 57,047
Open 0.8300
Bid (Size) 0.8170 (11)
Ask (Size) 0.8451 (2)
Prev. Close 0.8200
Today's Range 0.8140 - 0.8900
52wk Range 0.5933 - 9.988
Shares Outstanding 4,306,892
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Bio-Path Holdings Provides 2025 Clinical and Operational Update
From Bio-Path Holdings, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga

Performance

YTD
-28.35%
-28.35%
1 Month
-25.77%
-25.77%
3 Month
-22.99%
-22.99%
6 Month
-52.91%
-52.91%
1 Year
-89.95%
-89.95%

More News

Read More
Nasdaq Jumps 100 Points, US Initial Jobless Claims Decline
Via Benzinga
Bio-Path Holdings Shares Were On The Rise: What's Going On?
Via Benzinga
Gold Falls Sharply, Lamb Weston Shares Plunge
Via Benzinga
Uncovering Potential: Bio-Path Holdings's Earnings Preview
Via Benzinga
US Stocks Higher, Micron Reports Downbeat Sales
Via Benzinga
Bio-Path Holdings Announces Preclinical Testing of BP1001-A as Potential Treatment for Obesity in Type 2 Diabetes Patients Enhances Insulin Sensitivity
From Bio-Path Holdings, Inc.
Via GlobeNewswire
Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (BPTH) Q3 24
Via Newsfile
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Bio-Path Holdings Outlines Rationale for Development of BP1001-A as Potential Treatment for Obesity in Type 2 Diabetes Patients
From Bio-Path Holdings, Inc.
Via GlobeNewswire
Bio-Path Holdings Reports Third Quarter 2024 Financial Results
From Bio-Path Holdings, Inc.
Via GlobeNewswire
Earnings Scheduled For November 15, 2024
Via Benzinga
Bio-Path Holdings to Announce Third Quarter 2024 Financial Results on November 15, 2024
From Bio-Path Holdings, Inc.
Via GlobeNewswire
Bio-Path Holdings Announces Closing of $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules
From Bio-Path Holdings, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Bio-Path Holdings Announces $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules
From Bio-Path Holdings, Inc.
Via GlobeNewswire
Nasdaq Surges Over 1%; DocuSign Shares Spike Higher
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Crude Oil Falls Over 4%; US Trade Deficit Narrows In August
Via Benzinga
Exposures Fossil Fuels
US Stocks Edge Higher; PepsiCo Cuts 2024 Revenue Outlook
Via Benzinga
ACHR, BPTH, PLUG, REGRF:
Via News Direct
Nano-Cap Bio-Path Takes Plunge In Weight Loss Race, Initiates Obesity Program With Drug Candidate Under Development For Blood Cancer
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.